High Intensity Interval Versus Continuous Moderate Intensity Training: Maximizing the Benefits of Exercise in Overweight Adolescents

Not Applicable

Completed

• Conditions: Metabolism; Physical Fitness

• Registration Number: NCT01935323
• Lead Sponsor: University of Alabama at Birmingham

Brief Summary

6-week, single site, two parallel arm, randomized, controlled trial comparing the effectiveness of a High Intensity Interval Training (HIIT) versus a continuous Moderate Intensity Training (MIT) program on cardiovascular and metabolic health outcomes in overweight adolescent males. HIIT training may be a potent time-efficient strategy to induce similar metabolic and cardiovascular adaptations typically associated with MIT.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-02
• Study First Submitted: 2013-06-20
• Study First Submitted QC: 2013-08-30
• Study First Posted: 2013-09-05
• Primary Completion: 2014-10
• Study Completion: 2014-12
• Status Verified: 2016-01
• Last Update Submitted: 2016-01-08
• Last Update Posted: 2016-01-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 30

Inclusion Criteria

• Ages 17-22
• Men
• BMI (25.0 - 35.0 kg/m2)
• Interested in improving health and fitness

Exclusion Criteria

• Weight loss or gain of >10% of body weight in the past 6 months for any reason.
• Currently taking medication that suppresses or stimulates appetite.
• History of prior surgical procedure for weight control or liposuction.
• Current smoker.

Any major disease, including:

• Active cancer or cancer requiring treatment in the past 2 years (except nonmelanoma skin cancer).

• Active or chronic infections, including self-reported HIV positivity and active tuberculosis.

• Diagnosed heart conditions.

• Uncontrolled hypertension: systolic blood pressure 160 mm Hg or diastolic blood pressure 95 mm Hg on treatment.

• Gastrointestinal disease, including self-reported chronic hepatitis or cirrhosis, any episode of alcoholic hepatitis or alcoholic pancreatitis within past year, inflammatory bowel disease requiring treatment in the past year, recent or significant abdominal surgery (e.g., gastrectomy).

• Asthma.

• Diagnosed diabetes (type 1 or 2), fasting impaired glucose tolerance (blood glucose 118 mg/dL), or use of any anti-diabetic medications.

  • Conditions or behaviors likely to effect the conduct of the trial: unable or unwilling to give informed consent; unable to communicate with the pertinent clinic staff; unwilling to accept treatment assignment by randomization; current or anticipated participation in another intervention research project that would interfere with the intervention offered in the trial; likely to move away from participating clinics before trial completed; unable to walk 0.25 mile in 10 minutes.
  • Currently taking antidepressant, steroid, or thyroid medication, unless dosage is stable (no change for 6 months).
  • Any active use of illegal or illicit drugs.
  • Excessive alcohol intake defined as an average consumption of 3 or more alcohol containing beverages daily.
  • Unwilling to limit alcohol intake to ≤2 drink per day (one drink = 4 oz. wine, 12 oz. beer, or ½ shot of liquor).
  • Current exerciser (>30 min organized exercise per week).
  • Indication of unsuitability of current health for exercise protocol (PARQ).
  • Any other conditions which, in opinion of the investigators, would adversely affect the conduct of the trial.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Body Composition as measured by DXA	Baseline and 6 weeks

Secondary Outcome Measures

Name	Time	Method
Adiponectin	Baseline and 6 weeks
HDL Cholesterol	Baseline and 6 weeks
Body Weight	Baseline and 6 weeks
Blood Pressure	Baseline and 6 weeks
Peak uptake of volume of oxygen	Baseline and 6 weeks
Wingate Cycle test	Baseline and 6 weeks
Body Mass Index	Baseline and 6 weeks
LDL Cholesterol	Baseline and 6 weeks
Triglycerides	Baseline and 6 weeks
Insulin	Baseline and 6 weeks
Leptin	Baseline and 6 weeks
Glucose	Baseline and 6 weeks
Free living energy expenditure as measured by accelerometer	Baseline and 6 weeks
PYY	Baseline and 6 weeks
Protein Carbonyls	Baseline and 6 weeks	ELISA assay purchased from NW LifeSciences. Prior to analysis, all serum samples were assayed for protein concentration based on the methods of Bradford and adjusted to 4 mg・mL-1 protein using a phosphate buffer. Protein carbonyls, a measure of protein oxidation, were analyzed in duplicate in 50 μl of sera using a commercially available ELISA kit (NWK-PCK01).The intra- and interassay coefficients of variation were 2.7 % and 5%. The lower detection limit of the assay was 0.1 nmol/mg.
Quality & satisfaction with life	baseline & 6 weeks	composite score
Rate of perceived exertion during exercise via Borg Scale	baseline and 6 weeks
IL-6	Baseline and 6 weeks
TNF-alpha	Baseline and 6 weeks
Appetite/satiety measures	baseline & 6 weeks	composite score
24-hour dietary recall	pre-baseline, baseline, 6 weeks
Self Motivation Inventory	baseline and 6 weeks
Total antioxidant capacity	Baseline and 6 weeks
Profile of Mood States	baseline & 6 weeks
Ghrelin	Baseline and 6 weeks

Trial Locations

Locations (1)

UAB Physiology Lab; 🇺🇸 Birmingham, Alabama, United States